{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:47:26Z","timestamp":1791992846938,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.joca.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:00:58Z","timestamp":1783782058000},"page":"1642-1652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Signals for mineralization and inflammation are observed following treatment with fasinumab, a specific nerve growth factor inhibitor"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5304-9543","authenticated-orcid":false,"given":"Poulabi","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9165-9419","authenticated-orcid":false,"given":"Stephen J.","family":"DiMartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0486-6502","authenticated-orcid":false,"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1024-9792","authenticated-orcid":false,"given":"Tina","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4964-5729","authenticated-orcid":false,"given":"Simon","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-1032","authenticated-orcid":false,"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0095-2231","authenticated-orcid":false,"given":"Yamini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-748X","authenticated-orcid":false,"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2026.07.005_bib1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2026.07.005_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.33590\/emj\/10313855","article-title":"Osteoarthritis and ageing","volume":"3","author":"Valdes","year":"2018","journal-title":"Eur. Med. J."},{"key":"10.1016\/j.joca.2026.07.005_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.joca.2021.04.020","article-title":"Epidemiology of osteoarthritis","volume":"30","author":"Allen","year":"2022","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/rheumatology\/ket463","article-title":"Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries","volume":"53","author":"Kingsbury","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.joca.2026.07.005_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2174\/1874312901206010320","article-title":"Pain treatment in arthritis-related pain: beyond NSAIDs","volume":"6","author":"van Laar","year":"2012","journal-title":"Open. Rheumatol. J."},{"key":"10.1016\/j.joca.2026.07.005_bib6","article-title":"Inadequate pain relief among patients with primary knee osteoarthritis","author":"Laires","year":"2016","journal-title":"Rev. Bras. Reumatol."},{"key":"10.1016\/j.joca.2026.07.005_bib7","doi-asserted-by":"crossref","first-page":"iv99","DOI":"10.1093\/rheumatology\/kex522","article-title":"What is new in pain modification in osteoarthritis?","volume":"57","author":"Miller","year":"2018","journal-title":"Rheumatology"},{"issue":"107","key":"10.1016\/j.joca.2026.07.005_bib8","first-page":"85","article-title":"Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain","volume":"35","author":"Miller","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.joca.2026.07.005_bib9","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.3390\/ijms23094642","article-title":"Osteoarthritis pain","volume":"23","author":"Yu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.joca.2026.07.005_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.joca.2026.07.005_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","article-title":"Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial","volume":"80","author":"Dakin","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.joca.2026.07.005_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-neuro-072116-031121","article-title":"Nerve growth factor and pain mechanisms","volume":"40","author":"Denk","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.joca.2026.07.005_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780350315","article-title":"Nerve growth factor in the synovial fluid of patients with chronic arthritis","volume":"35","author":"Aloe","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.joca.2026.07.005_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1022475432077","article-title":"Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease","volume":"23","author":"Halliday","year":"1998","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.joca.2026.07.005_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.joca.2013.06.004","article-title":"Nerve growth factor: an update on the science and therapy","volume":"21","author":"Seidel","year":"2013","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib16","doi-asserted-by":"crossref","first-page":"10231","DOI":"10.1096\/fj.201900970","article-title":"Role of NGF-TrkA signaling in calcification of articular chondrocytes","volume":"33","author":"Jiang","year":"2019","journal-title":"Faseb J."},{"key":"10.1016\/j.joca.2026.07.005_bib17","first-page":"523","article-title":"Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study","volume":"7","author":"Tiseo","year":"2014","journal-title":"J. Pain Res."},{"key":"10.1016\/j.joca.2026.07.005_bib18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial","volume":"71","author":"Dakin","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.joca.2026.07.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2024.100533","article-title":"A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip","volume":"6","author":"DiMartino","year":"2024","journal-title":"Osteoarthr. Cartil. Open."},{"issue":"1","key":"10.1016\/j.joca.2026.07.005_bib20","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.joca.2003.11.003","article-title":"Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis","volume":"12","author":"Peterfy","year":"2004","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib22","unstructured":"US Food and Drug Administration, Summary Minutes of the Arthritis Advisory Committee Meeting March 12, 2012, 2012. https:\/\/web.archive.org\/web\/20161023214448\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM307879.pdf, (Accessed 27 June 2023)."},{"key":"10.1016\/j.joca.2026.07.005_bib23","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.joca.2024.07.001","article-title":"Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging","volume":"32","author":"DiMartino","year":"2024","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12891-025-08402-8","article-title":"Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip","volume":"26","author":"DiMartino","year":"2025","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.joca.2026.07.005_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006436","article-title":"A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip","volume":"12","author":"DiMartino","year":"2026","journal-title":"RMD Open"},{"key":"10.1016\/j.joca.2026.07.005_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rdc.2014.01.011","article-title":"Diagnosis and clinical manifestations of calcium pyrophosphate and basic calcium phosphate crystal deposition diseases","volume":"40","author":"Ea","year":"2014","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.joca.2026.07.005_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.joca.2020.04.020","article-title":"Cartilage calcification is associated with histological degeneration of the knee joint: a highly prevalent, age-independent systemic process","volume":"28","author":"Hubert","year":"2020","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.joca.2026.07.005_bib28","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/jor.23227","article-title":"Articular cartilage calcification of the humeral head is highly prevalent and associated with osteoarthritis in the general population","volume":"34","author":"Hawellek","year":"2016","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.joca.2026.07.005_bib29","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/art.24774","article-title":"Calcification of articular cartilage in human osteoarthritis","volume":"60","author":"Fuerst","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.joca.2026.07.005_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00256-004-0767-9","article-title":"Calcification in calcium pyrophosphate dihydrate (CPPD) crystalline deposits in the knee: anatomic, radiographic, MR imaging, and histologic study in cadavers","volume":"33","author":"Abreu","year":"2004","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.joca.2026.07.005_bib31","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1007\/s10067-018-4166-3","article-title":"Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation","volume":"37","author":"Frallonardo","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.joca.2026.07.005_bib32","first-page":"1925","article-title":"Interleukin-6 and chondrocyte mineralisation act in tandem to promote experimental osteoarthritis","volume":"74","author":"Nasi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.joca.2026.07.005_bib33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.joca.2014.02.938","article-title":"Calcium phosphate particulates increase friction in the rat knee joint","volume":"22","author":"Roemhildt","year":"2014","journal-title":"Osteoarthr. Cartil."}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458426009787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458426009787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:12:35Z","timestamp":1791990755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458426009787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1063458426009787"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2026.07.005","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signals for mineralization and inflammation are observed following treatment with fasinumab, a specific nerve growth factor inhibitor","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.","name":"copyright","label":"Copyright"}]}}